Chikungunya Vaccine Development May Rely On Immunologic Biomarkers Instead Of Traditional Trials
As the mosquito-borne chikungunya virus spreads into temperate regions worldwide, US FDA convenes advisory committee for an open discussion on development of vaccines.
You may also be interested in...
Epidemiology complicates field efficacy trials, but US FDA advisory committee members regretfully agree that data from non-human primate passive transfer studies is compelling but potentially insufficient for chikungunya vaccines.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The latest drug development news and highlights from our FDA Performance Tracker. Vaxchora cholera vaccine is CBER's fourth novel biologic cleared this year; Adamis emergency Epi turned down again.